Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(6):415; doi:10.1093/jnci/97.6.415
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Crawford to be Nominated as FDA Commissioner

President Bush has announced that he will nominate Lester M. Crawford, D.V.M., Ph.D., to be commissioner of the U.S. Food and Drug Administration. Crawford has been acting commissioner since March 2004, when the previous director, Mark McClellan, M.D., Ph.D., was confirmed . . . [Full Text of this Article]

Study Elucidates Function of BRCA2 Protein

Genetic Signature Could Identify Breast Cancer Patients at Risk of Recurrence


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?